UnitedHealth Group (NYSE:UNH) Given New $524.00 Price Target at JPMorgan Chase & Co.

UnitedHealth Group (NYSE:UNH) had its target price raised by equities researchers at JPMorgan Chase & Co. from $516.00 to $524.00 in a report released on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the healthcare conglomerate’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 30.34% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Jefferies Financial Group boosted their price target on shares of UnitedHealth Group from $401.00 to $490.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Royal Bank Of Canada boosted their target price on shares of UnitedHealth Group from $463.00 to $478.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Robert W. Baird lowered their price objective on UnitedHealth Group from $453.00 to $427.00 and set a “neutral” rating for the company in a research report on Wednesday. Bank of America restated a “buy” rating and set a $450.00 target price on shares of UnitedHealth Group in a research report on Monday, July 20th. Finally, Wall Street Zen upgraded UnitedHealth Group from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Twenty equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $461.76.

UnitedHealth Group Trading Down 1.1%

Shares of UNH stock traded down $4.64 on Friday, hitting $402.03. The company had a trading volume of 3,011,647 shares, compared to its average volume of 7,371,645. UnitedHealth Group has a twelve month low of $255.96 and a twelve month high of $461.62. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 0.74. The firm has a market cap of $360.86 billion, a P/E ratio of 22.93, a P/E/G ratio of 1.43 and a beta of 0.60. The stock’s 50-day moving average is $387.17 and its two-hundred day moving average is $384.52.

UnitedHealth Group (NYSE:UNH) last announced its earnings results on Tuesday, October 13th. The healthcare conglomerate reported $4.69 EPS for the quarter, beating the consensus estimate of $4.14 by $0.55. The business had revenue of $112.70 billion for the quarter, compared to analysts’ expectations of $111.31 billion. UnitedHealth Group had a return on equity of 17.95% and a net margin of 3.53%. The firm’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $2.59 earnings per share. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. On average, equities research analysts anticipate that UnitedHealth Group will post 20.66 earnings per share for the current fiscal year.

Insider Activity at UnitedHealth Group

In other news, CEO Patrick Conway sold 1,169 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $390.00, for a total transaction of $455,910.00. Following the transaction, the chief executive officer directly owned 15,328 shares of the company’s stock, valued at $5,977,920. This represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.19% of the stock is currently owned by corporate insiders.

Institutional Trading of UnitedHealth Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. General Partner Inc. purchased a new stake in shares of UnitedHealth Group during the 3rd quarter worth approximately $512,000. PBCay One RSC Ltd bought a new stake in shares of UnitedHealth Group in the first quarter valued at $14,343,000. Lee Johnson Capital Management LLC bought a new stake in shares of UnitedHealth Group in the second quarter valued at $6,180,000. Kinsale Capital Group Inc. lifted its position in shares of UnitedHealth Group by 13.4% during the 2nd quarter. Kinsale Capital Group Inc. now owns 38,510 shares of the healthcare conglomerate’s stock valued at $16,006,000 after buying an additional 4,557 shares during the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. grew its stake in shares of UnitedHealth Group by 1,287.2% during the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 60,022 shares of the healthcare conglomerate’s stock worth $16,241,000 after acquiring an additional 55,695 shares during the period. Institutional investors own 87.86% of the company’s stock.

Key Stories Impacting UnitedHealth Group

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Earnings beat and raised outlook: UnitedHealth reported third-quarter adjusted earnings of $4.69 per share versus a $4.14 consensus estimate, while revenue reached $112.7 billion. Management raised its 2026 adjusted earnings outlook to at least $20.50 per share from a previous $19.50–$20.00 range, supporting optimism about margin recovery. UnitedHealth Group gains after Q3 beat and higher 2026 outlook
• Positive Sentiment: Bullish analyst support: Piper Sandler maintained an overweight stance and raised its price target to $504, while Goldman Sachs reportedly lifted its target to $506 after the earnings beat. These targets imply meaningful potential upside from recent trading levels. Piper Sandler analyst says UnitedHealth stock price is expected to rise
• Neutral Sentiment: Potential Medicare growth: Analysts see UnitedHealth’s focus on Medicare special-needs plans, broader coverage and improved margins as possible growth drivers in 2027, but medical-cost and Medicaid pressures remain important execution risks. Can UNH’s Focus on Special Needs Plans Strengthen Medicare Growth?
• Negative Sentiment: Growth concerns remain: Despite the earnings beat, investors are questioning UnitedHealth’s longer-term growth path as membership shrinks and commercial medical costs and Medicaid pressures weigh on profitability. Commentary also argues that much of the positive earnings news may already be reflected in the valuation. UnitedHealth beats on earnings, but investors question growth path
• Negative Sentiment: Mixed Wall Street signals: Barclays issued a pessimistic forecast and Robert W. Baird cut its price target, contrasting with the bullish Piper Sandler and Goldman Sachs calls. TD Cowen reaffirmed a hold rating with a $402 target, indicating limited near-term upside in that firm’s view. Barclays issues pessimistic forecast for UnitedHealth

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.